BioArctic

BioArctic Retained Earnings

The Retained Earnings of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 1.35 B SEK. In the previous year, Retained Earnings was 305.11 M SEK — a change of 342.93% (higher).

Retained Earnings

1.35 BSEK

YoY

342.93%

Last updated:

Retained Earnings of BioArctic is 2025 1.35 B SEK. Retained Earnings of BioArctic was 2024 305.11 M SEK. It decreases by 342.93% higher compared to the previous year.

The BioArctic Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
455.00 M SEK
Jan 1, 2019
411.76 M SEK
Jan 1, 2020
344.56 M SEK
Jan 1, 2021
225.94 M SEK
Jan 1, 2022
217.52 M SEK
Jan 1, 2023
462.87 M SEK
Jan 1, 2024
305.11 M SEK
Jan 1, 2025
1.35 B SEK
The BioArctic Retained Earnings history
YEARRetained EarningsYoY
1.35 BSEK+342.93%
305.11 MSEK-34.08%
462.87 MSEK+112.80%
217.52 MSEK-3.73%
225.94 MSEK-34.43%
344.56 MSEK-16.32%
411.76 MSEK-9.50%
455.00 MSEK+519.91%
73.40 MSEK+22.95%
59.70 MSEK-44.32%
107.22 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Retained Earnings of BioArctic is 1.35 B SEK in 2025.

Retained Earnings of BioArctic changed from 305.11 M SEK to 1.35 B SEK, representing a 342.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings BioArctic since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioArctic

All Key Metrics — BioArctic